{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:20:52Z","timestamp":1772119252479,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"University of Arizona Cancer Center Support Grant , NCI","award":["P30CA023074"],"award-info":[{"award-number":["P30CA023074"]}]},{"name":"University of Arizona Cancer Center Support Grant , NCI","award":["P30CA023074"],"award-info":[{"award-number":["P30CA023074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00280-024-04688-y","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T03:02:42Z","timestamp":1718420562000},"page":"361-372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies"],"prefix":"10.1007","volume":"94","author":[{"given":"Megan J.","family":"Cracchiolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Matiatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan W.","family":"Davini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Husnain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7064-6881","authenticated-orcid":false,"given":"Richard J.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios","family":"Voudouris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1466-6965","authenticated-orcid":false,"given":"Emmanuel","family":"Katsanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"issue":"5","key":"4688_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00432-002-0331-8","volume":"128","author":"SM Konstantinov","year":"2002","unstructured":"Konstantinov SM et al (2002) Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 128(5):271\u2013278","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"4688_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM et al (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14(1):309\u2013317","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4688_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","volume":"7","author":"D Strumberg","year":"1996","unstructured":"Strumberg D et al (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7(4):415\u2013421","journal-title":"Anticancer Drugs"},{"issue":"2","key":"4688_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1586\/ehm.10.7","volume":"3","author":"M Montillo","year":"2010","unstructured":"Montillo M et al (2010) Bendamustine: new perspective for an old drug in lymphoproliferative disorders. Expert Rev Hematol 3(2):131\u2013148","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"4688_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/ejh.12609","volume":"95","author":"M Gentile","year":"2015","unstructured":"Gentile M et al (2015) Bendamustine in multiple myeloma. Eur J Haematol 95(5):377\u2013388","journal-title":"Eur J Haematol"},{"issue":"6 Suppl 5","key":"4688_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2007.11.001","volume":"34","author":"BD Cheson","year":"2007","unstructured":"Cheson BD (2007) Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies. Semin Oncol 34(6 Suppl 5):S3-7","journal-title":"Semin Oncol"},{"issue":"3","key":"4688_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00280-010-1317-x","volume":"66","author":"N Tageja","year":"2010","unstructured":"Tageja N, Nagi J (2010) Bendamustine: something old, something new. Cancer Chemother Pharmacol 66(3):413\u2013423","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 1","key":"4688_CR8","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1053\/j.seminhematol.2011.03.003","volume":"48","author":"LM Leoni","year":"2011","unstructured":"Leoni LM, Hartley JA (2011) Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. Semin Hematol 48(Suppl 1):S12-23","journal-title":"Semin Hematol"},{"key":"4688_CR9","unstructured":"Cephalon Product characteristics for BENDEKA and TREANDA (bendamustine HCl). 2020 2019. https:\/\/www.bendekahcp.com\/globalassets\/bendeka-hcp\/resources-page\/bendeka-treanda-product-characteristics.pdf. Accessed 14 sept 2023"},{"issue":"Suppl 1","key":"4688_CR10","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1053\/j.seminhematol.2011.03.002","volume":"48","author":"LM Leoni","year":"2011","unstructured":"Leoni LM (2011) Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol 48(Suppl 1):S4-11","journal-title":"Semin Hematol"},{"issue":"6","key":"4688_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00280-015-2727-6","volume":"75","author":"M Darwish","year":"2015","unstructured":"Darwish M et al (2015) Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol 75(6):1143\u20131154","journal-title":"Cancer Chemother Pharmacol"},{"key":"4688_CR12","doi-asserted-by":"publisher","first-page":"887648","DOI":"10.3389\/fimmu.2022.887648","volume":"13","author":"J Stokes","year":"2022","unstructured":"Stokes J, Simpson RJ, Katsanis E (2022) Commentary: post-transplantation cyclophosphamide uniquely restrains alloreactive CD4+ T-cell proliferation and differentiation after murine MHC-haploidentical hematopoietic cell transplantation. Front Immunol 13:887648","journal-title":"Front Immunol"},{"issue":"8","key":"4688_CR13","doi-asserted-by":"publisher","first-page":"e0273075","DOI":"10.1371\/journal.pone.0273075","volume":"17","author":"MS Molina","year":"2022","unstructured":"Molina MS et al (2022) Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1\/PD-L1 pathway. PLoS ONE 17(8):e0273075","journal-title":"PLoS ONE"},{"issue":"7","key":"4688_CR14","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/cancers13071702","volume":"13","author":"J Stokes","year":"2021","unstructured":"Stokes J et al (2021) Immunomodulatory effects of bendamustine in hematopoietic cell transplantation. Cancers (Basel) 13(7):1702","journal-title":"Cancers (Basel)"},{"key":"4688_CR15","doi-asserted-by":"publisher","first-page":"699128","DOI":"10.3389\/fimmu.2021.699128","volume":"12","author":"MS Molina","year":"2021","unstructured":"Molina MS et al (2021) Regulatory dendritic cells induced by bendamustine are associated with enhanced Flt3 expression and alloreactive T-cell death. Front Immunol 12:699128","journal-title":"Front Immunol"},{"issue":"1","key":"4688_CR16","doi-asserted-by":"publisher","first-page":"1758011","DOI":"10.1080\/2162402X.2020.1758011","volume":"9","author":"J Stokes","year":"2020","unstructured":"Stokes J et al (2020) Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia. Oncoimmunology 9(1):1758011","journal-title":"Oncoimmunology"},{"key":"4688_CR17","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3389\/fimmu.2020.01410","volume":"11","author":"MS Molina","year":"2020","unstructured":"Molina MS et al (2020) Bendamustine conditioning skews murine host DCs toward pre-cDC1s and reduces GvHD independently of Batf3. Front Immunol 11:1410","journal-title":"Front Immunol"},{"issue":"3","key":"4688_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.bbmt.2018.10.009","volume":"25","author":"J Stokes","year":"2019","unstructured":"Stokes J et al (2019) Bendamustine with total body irradiation limits murine graft-versus-host disease in part through effects on myeloid-derived suppressor cells. Biol Blood Marrow Transplant 25(3):405\u2013416","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4688_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bjh.14034","volume":"174","author":"J Stokes","year":"2016","unstructured":"Stokes J et al (2016) Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation. Br J Haematol 174(1):102\u2013116","journal-title":"Br J Haematol"},{"issue":"9","key":"4688_CR20","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","volume":"33","author":"G Ghilardi","year":"2022","unstructured":"Ghilardi G et al (2022) Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann Oncol 33(9):916\u2013928","journal-title":"Ann Oncol"},{"key":"4688_CR21","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/ajh.27069","volume":"98","author":"SY Ong","year":"2023","unstructured":"Ong SY et al (2023) Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma. Am J Hematol 98:1751","journal-title":"Am J Hematol"},{"issue":"8","key":"4688_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s11912-023-01404-6","volume":"25","author":"S Green","year":"2023","unstructured":"Green S, Schultz L (2023) Rational alternatives to fludarabine and cyclophosphamide-based Pre-CAR lymphodepleting regimens in the pediatric and young adult B-ALL setting. Curr Oncol Rep 25(8):841\u2013846","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"4688_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10637-022-01307-6","volume":"41","author":"T Shimizu","year":"2023","unstructured":"Shimizu T et al (2023) Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study. Invest New Drugs 41(1):1\u201312","journal-title":"Invest New Drugs"},{"issue":"8","key":"4688_CR24","doi-asserted-by":"publisher","first-page":"e5387","DOI":"10.1002\/bmc.5387","volume":"36","author":"HK Tripathy","year":"2022","unstructured":"Tripathy HK et al (2022) Validated liquid chromatography-tandem mass spectrometry method for simultaneous quantitation of bendamustine and copanlisib in mouse plasma: application to a pharmacokinetic study in mice. Biomed Chromatogr 36(8):e5387","journal-title":"Biomed Chromatogr"},{"key":"4688_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jchromb.2012.02.039","volume":"893\u2013894","author":"AC Dubbelman","year":"2012","unstructured":"Dubbelman AC et al (2012) Development and validation of LC-MS\/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 893\u2013894:92\u2013100","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"282","key":"4688_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric-estimation from incomplete observations. J Am Stat Assoc 53(282):457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"4688_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2307\/2344317","volume":"135","author":"R Peto","year":"1972","unstructured":"Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures. J Royal Stat Soc Ser General 135:185\u2013190","journal-title":"J Royal Stat Soc Ser General"},{"issue":"11","key":"4688_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","volume":"128","author":"K Bremer","year":"2002","unstructured":"Bremer K (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin\u2019s-lymphomas. J Cancer Res Clin Oncol 128(11):603\u2013609","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"4688_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40268-012-0001-5","volume":"13","author":"AC Dubbelman","year":"2013","unstructured":"Dubbelman AC et al (2013) Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy. Drugs R D 13(1):17\u201328","journal-title":"Drugs R D"},{"issue":"5","key":"4688_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4155\/tde.11.19","volume":"2","author":"JA Yanez","year":"2011","unstructured":"Yanez JA et al (2011) Flip-flop pharmacokinetics\u2013delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv 2(5):643\u2013672","journal-title":"Ther Deliv"},{"issue":"9","key":"4688_CR31","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1002\/jps.24505","volume":"104","author":"KL Garrison","year":"2015","unstructured":"Garrison KL, Sahin S, Benet LZ (2015) Few drugs display flip-flop pharmacokinetics and these are primarily associated with classes 3 and 4 of the BDDCS. J Pharm Sci 104(9):3229\u20133235","journal-title":"J Pharm Sci"},{"issue":"4","key":"4688_CR32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","volume":"13","author":"LZ Benet","year":"2011","unstructured":"Benet LZ, Broccatelli F, Oprea TI (2011) BDDCS applied to over 900 drugs. AAPS J 13(4):519\u2013547","journal-title":"AAPS J"},{"issue":"1","key":"4688_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1055\/a-0640-8977","volume":"69","author":"RK Jairam","year":"2019","unstructured":"Jairam RK et al (2019) Prediction of human pharmacokinetics of bendamustine from preclinical species pharmacokinetics based on normalizing time course profiles. Drug Res (Stuttg) 69(1):32\u201339","journal-title":"Drug Res (Stuttg)"},{"issue":"6","key":"4688_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00280-006-0331-5","volume":"59","author":"J Teichert","year":"2007","unstructured":"Teichert J et al (2007) Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 59(6):759\u2013770","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4688_CR35","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1124\/dmd.105.009035","volume":"34","author":"M Martignoni","year":"2006","unstructured":"Martignoni M, Groothuis G, de Kanter R (2006) Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug Metab Dispos 34(6):1047\u20131054","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"4688_CR36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","volume":"123","author":"H Ludwig","year":"2014","unstructured":"Ludwig H et al (2014) Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123(7):985\u2013991","journal-title":"Blood"},{"key":"4688_CR37","doi-asserted-by":"publisher","first-page":"104040","DOI":"10.1016\/j.critrevonc.2023.104040","volume":"187","author":"BA Costa","year":"2023","unstructured":"Costa BA et al (2023) Revisiting the role of alkylating agents in multiple myeloma: up-to-date evidence and future perspectives. Crit Rev Oncol Hematol 187:104040","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4688_CR38","first-page":"36","volume":"5","author":"B Cai","year":"2013","unstructured":"Cai B et al (2013) Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. Am J Transl Res 5(1):36\u201346","journal-title":"Am J Transl Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04688-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04688-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04688-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T15:02:38Z","timestamp":1727103758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04688-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["4688"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04688-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3848777\/v1","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors MJC, LD, APM, DWD, MH, RJS, and EK declare no conflicts of interest regarding authorship or publication of this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}